NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
21.76
-0.65 (-2.90%)
At close: Mar 28, 2025, 4:00 PM
20.86
-0.90 (-4.13%)
Pre-market: Mar 31, 2025, 7:40 AM EDT
NAMS Employees
NewAmsterdam Pharma Company had 68 employees as of December 31, 2024. The number of employees increased by 39 or 134.48% compared to the previous year.
Employees
68
Change (1Y)
39
Growth (1Y)
134.48%
Revenue / Employee
$670,044
Profits / Employee
-$3,552,912
Market Cap
2.39B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 68 | 39 | 134.48% |
| Dec 31, 2023 | 29 | 12 | 70.59% |
| Dec 31, 2022 | 17 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NAMS News
- 4 weeks ago - NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib - Seeking Alpha
- 4 weeks ago - NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution - Seeking Alpha
- 4 weeks ago - NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - GlobeNewsWire
- 7 weeks ago - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 3 months ago - NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 3 months ago - NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts - Seeking Alpha